SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (1682)11/10/2014 7:33:11 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
Well, trial did experience protocol changes during the course, but standard (LDL-C<70) versus aggressive (LDL<50) sub-population outcome (regardless is it from aggressive statin or added Zieta) will help determine is surrogate LDL-C good predictor of medical benefit. Looking forward for results. I am not sure whether the AHA presentation will be webcasted on-line.